PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
6.46
P/E exceeding 1.5x Medical - Pharmaceuticals median of 4.18. Michael Burry would check for market euphoria. Scrutinize growth expectations.
0.59
P/S less than half the Medical - Pharmaceuticals median of 7.14. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
1.22
P/B 50-90% of Medical - Pharmaceuticals median of 1.43. Mohnish Pabrai would examine if this discount presents opportunity.
-19.04
Negative FCF while Medical - Pharmaceuticals median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-136.97
Negative operating cash flow while Medical - Pharmaceuticals median P/OCF is 3.58. Seth Klarman would investigate operational improvement potential.
1.22
Fair value ratio 50-90% of Medical - Pharmaceuticals median of 1.43. Mohnish Pabrai would examine if this gap presents opportunity.
3.87%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 1.20%. Joel Greenblatt would investigate if high yield reflects hidden value.
-5.25%
Negative FCF while Medical - Pharmaceuticals median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.